US FDA’s April Outlook: Decisions Pending For Rare Pediatric Diseases, New Antibiotics

 
• By Bridget Silverman
  
fresh-branches-of-a-bud-and-young-leaves-with-raindrops
There are not a deluge of NMEs that could be approved in April, but they offer green shoots nonetheless. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Archive

More from Pink Sheet